Andrea Eisen

15.6k total citations · 1 hit paper
189 papers, 8.3k citations indexed

About

Andrea Eisen is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Andrea Eisen has authored 189 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Genetics, 84 papers in Oncology and 65 papers in Cancer Research. Recurrent topics in Andrea Eisen's work include BRCA gene mutations in cancer (91 papers), Breast Cancer Treatment Studies (52 papers) and Global Cancer Incidence and Screening (31 papers). Andrea Eisen is often cited by papers focused on BRCA gene mutations in cancer (91 papers), Breast Cancer Treatment Studies (52 papers) and Global Cancer Incidence and Screening (31 papers). Andrea Eisen collaborates with scholars based in Canada, United States and Poland. Andrea Eisen's co-authors include Steven A. Narod, William D. Foulkes, Ellen Warner, Henry T. Lynch, Barbara Weber, Nadine Tung, Olufunmilayo I. Olopade, Kelly Metcalfe, Claudine Isaacs and Ping Sun and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andrea Eisen

179 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update

2025 18 citations Ko Un Park, Mark R. Somerfield et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Andrea Eisen

Since Specialization

Citations

This map shows the geographic impact of Andrea Eisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Eisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Eisen more than expected).

Fields of papers citing papers by Andrea Eisen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Eisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Eisen. The network helps show where Andrea Eisen may publish in the future.

Co-authorship network of co-authors of Andrea Eisen

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Eisen. A scholar is included among the top collaborators of Andrea Eisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Eisen. Andrea Eisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update breakdown → 2025 ·Journal of Clinical Oncology ·Ko Un Park, Mark R. Somerfield, (unknown), Muriel Brackstone, Alison Conlin, (unknown), Lynn T. Dengel, Andrea Eisen, Brittany Harvey, Jeffrey Hawley, (unknown), (unknown), Elizabeth S. McDonald, Deepti Pradhan, (unknown), Raymond B. Mailhot Vega, Alastair M. Thompson, Mylin A. Torres	18
2	Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study 2025 ·Cancers ·Daniel Moore-Palhares, Lakshmanan Sannachi, Adrian Wai Chan, Archya Dasgupta, Daniel DiCenzo, Sonal Gandhi, Rossanna C. Pezo, Andrea Eisen, Ellen Warner, Frances C. Wright, Nicole Look Hong, Ali Sadeghi‐Naini, Mia Skarpathiotakis, Belinda Curpen, (unknown), Michael C. Kolios, Maureen Trudeau, Gregory J. Czarnota	0
3	Prediction of Chemotherapy Response in Locally Advanced Breast Cancer Patients at Pre-Treatment Using CT Textural Features and Machine Learning: Comparison of Feature Selection Methods 2025 ·Tomography ·(unknown), (unknown), Archya Dasgupta, (unknown), (unknown), Maureen Trudeau, Sonal Gandhi, Andrea Eisen, Frances C. Wright, (unknown), Belinda Curpen, Michael C. Kolios, Gregory J. Czarnota	0
4	Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer 2024 ·Current Oncology ·(unknown), (unknown), (unknown), Andrea Eisen, (unknown), Scott Gavura, Kelvin Chan	2
5	Apriori prediction of chemotherapy response in locally advanced breast cancer patients using CT imaging and deep learning: transformer versus transfer learning 2024 ·Frontiers in Oncology ·(unknown), (unknown), Archya Dasgupta, (unknown), Maureen Trudeau, Sonal Gandhi, Andrea Eisen, Frances W. Wright, (unknown), Belinda Curpen, Michael C. Kolios, Gregory J. Czarnota	4
6	Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update 2024 ·Journal of Clinical Oncology ·Rachel A. Freedman, Jennifer L. Caswell‐Jin, Michael J. Hassett, Mark R. Somerfield, Sharon H. Giordano, (unknown), Mariana Chávez‐MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, (unknown), Stephanie L. Graff, Tari A. King, Gary H. Lyman, (unknown), Cheryl Perkins, Melinda L. Telli, Maureen Trudeau, Antonio C. Wolff, (unknown)	18
7	Rates of genetic consultation in high‐grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population‐based study 2024 ·International Journal of Gynecology & Obstetrics ·Shannon E. Brent, Jacob McGee, Danielle Vicus, Raymond H. Kim, Andrea Eisen, Andrew S. Wilton, Lilian T. Gien	1
8	203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial 2023 ·ESMO Open ·Karen A. Gelmon, PA Fasching, Suzette Delaloge, Y.H. Park, Andrea Eisen, Hugues Bourgeois, Zoe Kemp, (unknown), Joohyuk Sohn, Sercan Aksoy, Constanta Timcheva, (unknown), A. Antón Torres, (unknown), (unknown), Natalia Lukashchuk, (unknown), Judith Balmañà	1
9	Preoperative Breast Magnetic Resonance Imaging: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline 2023 ·Current Oncology ·Derek Muradali, Glenn G. Fletcher, Erin Cordeiro, (unknown), Ralph George, Supriya Kulkarni, Jean M. Seely, (unknown), Andrea Eisen	5
10	Breast Magnetic Resonance Imaging for Preoperative Evaluation of Breast Cancer: A Systematic Review and Meta-Analysis 2023 ·Canadian Association of Radiologists Journal ·Andrea Eisen, Glenn G. Fletcher, (unknown), Ralph George, Claire Holloway, Supriya Kulkarni, Jean M. Seely, Derek Muradali	12
11	Identifying Breast Cancer Recurrence in Administrative Data: Algorithm Development and Validation 2022 ·Current Oncology ·Claire Holloway, (unknown), María Eberg, Katharina Förster, Paula Murray, (unknown), (unknown), Andrea Eisen, Jonathan Sussman	6
12	Factors associated with waiting time to breast cancer diagnosis among symptomatic breast cancer patients: a population-based study from Ontario, Canada 2021 ·Breast Cancer Research and Treatment ·Colleen Webber, Marlo Whitehead, Andrea Eisen, (unknown), Patti A. Groome	6
13	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers 2021 ·Cancer Epidemiology Biomarkers & Prevention ·Shana J. Kim, Jan Lubiński, Tomasz Huzarski, Pål Møller, Susan Randall Armel, Beth Y. Karlan, Leigha Senter, Andrea Eisen, William D. Foulkes, Christian F. Singer, Nadine Tung, Louise Bordeleau, Susan L. Neuhausen, Olufunmilayo I. Olopade, Charis Eng, Jeffrey N. Weitzel, Robert Fruscio, Steven A. Narod, Joanne Kotsopoulos	7
14	Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program 2021 ·The Breast Journal ·(unknown), (unknown), (unknown), Jane K. Mills, Andrea Eisen, Derek Muradali, Eva Grunfeld, Adena Scheer	2
15	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update 2020 ·Journal of Clinical Oncology ·Neelima Denduluri, Mark R. Somerfield, Mariana Chávez‐MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, (unknown), Stephanie L. Graff, Michael J. Hassett, Tari A. King, Gary H. Lyman, (unknown), Raquel Nunes, Cheryl Perkins, Melinda L. Telli, Maureen Trudeau, Antonio C. Wolff, Sharon H. Giordano	76
16	Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program 2019 ·JNCI Journal of the National Cancer Institute ·Anna M. Chiarelli, Kristina M. Blackmore, Derek Muradali, Susan J. Done, Vicky Majpruz, Ashini Weerasinghe, Lucia Mirea, Andrea Eisen, Linda Rabeneck, Ellen Warner	56
17	Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program 2018 ·Molecular Genetics & Genomic Medicine ·Andrea Eisen, Kristina M. Blackmore, Wendy S. Meschino, Derek Muradali, June Carroll, Vicky Majpruz, Ellen Warner, Linda Rabeneck, Anna M. Chiarelli	7
18	Preferential Killing of Breast Tumor Initiating Cells by N,N -Diethyl-2-[4-(Phenylmethyl)Phenoxy]Ethanamine/Tesmilifene 2008 ·Clinical Cancer Research ·Tao Deng, Jeff C. Liu, Kathleen I. Pritchard, Andrea Eisen, Eldad Zacksenhaus	19
19	Variation in Rates of Uptake of Preventive Options in BRCA1 and BRCA2 Mutation Carriers Across Canada 2007 ·Kelly Metcalfe, Parviz Ghadirian, Barry P. Rosen, William D. Foulkes, Charmaine Kim‐Sing, Andrea Eisen, Peter Ainsworth, Doug Horsman, Christine Maugard, Diane Provencher, (unknown), Dawna Gilchrist, Albert E. Chudley, Edmond G. Lemire, Susan Randall Armel, Amy Finch, Ping Sun, Steven A. Narod	8
20	The Risk of Ovarian Cancer After Breast Cancer in BRCA1 and BRCA2 Carriers 2005 ·Obstetrical & Gynecological Survey ·Kelly Metcalfe, Henry T. Lynch, P Ghadirian, Nadine Tung, Ivo A. Olivotto, William D. Foulkes, Ellen Warner, Olufunmilayo I. Olopade, Andrea Eisen, (unknown), Jane McLennan, Ping Sun, Steven A. Narod	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact